Given that some antidiabetic medications, such as SGLT-2 inhibitors [49], will reduce the risk of ischemic heart disease in diabetes patients, future studies considering antidiabetic medication are still needed to validate the genetic effect on diabetic macrovascular complications. Here, SLC5A2 is linked to coronary artery disorder.